Takeda Pharmaceutical (NYSE:TAK) General Counsel Natalie Anne Marie Furney Sells 30,868 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) General Counsel Natalie Anne Marie Furney sold 30,868 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $527,842.80. Following the transaction, the general counsel directly owned 204,298 shares in the company, valued at $3,493,495.80. This trade represents a 13.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Down 0.3%

TAK opened at $17.42 on Thursday. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The business’s 50-day moving average price is $16.49 and its 200-day moving average price is $17.13. The company has a market cap of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The company had revenue of $6.90 billion during the quarter. On average, equities analysts expect that Takeda Pharmaceutical Co. will post 3.01 EPS for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of TAK. Private Trust Co. NA grew its position in shares of Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after buying an additional 783 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in shares of Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after buying an additional 1,684 shares during the period. SHP Wealth Management bought a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $42,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Takeda Pharmaceutical by 313.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after acquiring an additional 2,328 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after acquiring an additional 1,292 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on TAK. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold”.

Takeda Pharmaceutical News Roundup

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Neutral Sentiment: The sales were explicitly made to cover tax-withholding obligations tied to the vesting of equity awards, rather than representing discretionary open-market selling. Each insider retained a substantial stake after the transactions, reducing the concern that management is broadly abandoning the company. SEC insider filing
• Negative Sentiment: The volume and seniority of the sellers could weigh on investor sentiment. CEO Julie So-Young Kim sold 89,090 shares, while Andrew Stewart Plump sold 165,393 shares. General Counsel Natalie Anne Marie Furney, Giles Richard Platford, Lauren Rusckowski Duprey and several other insiders also reduced their holdings, with individual ownership declines ranging from about 6.6% to 18.5%. SEC insider filing

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.